US-based Mustang Bio, Inc. has announced a strategic partnership with uBriGene (Boston) Biosciences Inc., the US subsidiary of China-based uBriGene, a leading cell and gene therapy contract development and manufacturing organization (CDMO). This deal will result in the sale of Mustang’s development, manufacturing, and analytical testing facility in Worcester, Massachusetts to uBriGene, marking a significant step in the expansion of both companies’ capabilities in the cell and gene therapy sector.
uBriGene’s Focus on Cell and Gene Therapy
Founded in 2015, uBriGene has been focused on the cell and gene therapy (CGT) field, raising significant capital in Series C and C+ financing rounds, amounting to hundreds of millions of renminbi and RMB 150 million, respectively. This funding has supported the company’s growth and development in the rapidly evolving CGT space.
Mustang Bio, Inc.’s Clinical-Stage Focus on Cell and Gene Therapies
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company’s expertise and focus on these areas position it well to capitalize on the growing demand for advanced therapies in the global market.
The Growing Importance of the Cell and Gene Therapy Field
The cell and gene therapy field is expected to be worth USD 3.54 billion globally by 2025, highlighting the importance of partnerships like the one between Mustang Bio and uBriGene. Such collaborations are crucial for driving innovation and expanding access to life-changing treatments for patients worldwide.-Fineline Info & Tech
